35

antibody, an anti-IL-13R or antibody and an anti-CD4 antibody conjugate.

- 3. The method of claim 2, wherein said second and/or third nucleic acid contains hybrid intronic nucleic acid sequence.
- **4**. The method of claim **2**, characterized in that said first transfection vector and said second transfection vector differ only in the nucleic acid conferring resistance to said eukaryotic selection agent.
- 5. The method of claim 2, wherein step c) and step d) are performed in the same medium.
- 6. The method of claim 5, wherein said medium is selected form the group consisting of a serum-free medium, a serum-free medium supplemented with defined animal-derived components, an animal-derived component free medium, a protein-free medium supplemented with defined animal-derived components, a defined protein-free medium, and a chemically defined medium.
- 7. The method of, claim 2, wherein the cultivating of step d) is either in the presence of the eukaryotic selection agents in a volume of less than 500 liter or said cultivating is in the absence of said eukaryotic selection agents in a volume of 500

36

liter or more, and that the recovering of the secreted heterologous immunoglobulin is from the cultivation medium without said eukaryotic selection agents.

- 8. The method of claim 2, characterized in that the productivity of said CHO cells is over 40 generations not less than 70% and not more than 130% of the productivity after 10 generations of cultivation as split-batch cultivation.
- 9. The method of claim 8, characterized in that the productivity of said CHO cell is at least 1.5 g/I of said heterologous immunoglobulin within 21 days as fed-batch cultivation.
 - 10. The method of claim 1, characterized in that said method further comprises:
 - f) purifying said heterologous immunoglobulin with one or more chromatographic steps.
 - 11. The method of claim 10, characterized in that said transfected CHO cell of step c) has
 - a doubling time of 150% or less of the doubling time of the CHO cell selected in substep (ii),
 - a volumetric yield of at least 125% compared to the volumetric yield of the CHO cell selected in (ii).

* * * * *